Quality of Life in Cancer Patients with or Without Medication-related Osteonecrosis of the Jaw

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2021 May 11

PMID 33973080

Citations 7

Authors

Sara de Cassia Tornier

Fernanda Joly Macedo

Laurindo Moacir Sassi

Juliana Lucena Schussel

Affiliations

Soon will be listed here.

Abstract

Purpose: Cancer and its therapies can have a significant impact on general and oral health and, therefore, cause a reduction in patients' quality of life (QoL). The study aimed to evaluate the QoL of cancer patients who use antiresorptive and anti-angiogenic medications with or without the development of medication-related osteonecrosis of the jaws (MRONJ).

Methods: Sixty-two patients diagnosed with cancer under antiresorptive therapy answered three instruments from the European Organization for Cancer Research and Treatment (EORTC). The first questionnaire (QLQ-C30) aimed to measure the overall QoL, the second (QLQ-ELD14) is a complementary module for elderly patients, and the third (QLQ-OH15) aimed to assess oral health related to QoL.

Results: The mean age of the patients was 62.19 years, and 12.9% developed MRONJ. There was no significant difference between sex and MRONJ. Among the QLQ-C30 scales, the item "role functioning (RF2)" presented a significant result (p = 0.019). Those patients without MRONJ had a better function performance both in their daily chores and in their free time. Age was not associated to MRONJ, although some concerns are common to the elderly and cancer patients. QoL related to oral health presented a significant result (p = 0.048) showing that MRONJ has a negative impact on patients' QoL.

Conclusion: Our results showed that MRONJ has a significant impact on the general and oral QoL of cancer patients, and therefore prevention and awareness must be a priority.

Citing Articles

Education and Communication on the Topic of Osteonecrosis of the Jaw When Taking Bone-Stabilizing Drugs.

Saur F, Keinki C, Cramer A, Buentzel J, Hubner J Clin Exp Dent Res. 2024; 10(6):e70024.

PMID: 39497340 PMC: 11534630. DOI: 10.1002/cre2.70024.

Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study.

Brunner C, Arvandi M, Marth C, Egle D, Baumgart F, Emmelheinz M J Clin Oncol. 2024; 43(2):180-188.

PMID: 39163561 PMC: 11708989. DOI: 10.1200/JCO.24.00171.

Improvement of Quality of Life after Surgical Treatment of Patients with MRONJ: A Prospective Analysis Using the SF-12 and OHIP-14 Questionnaires.

Hoene G, von Hahn N, Sievers D, Schuffelen L, Wolfer S, Goldstein K Int J Dent. 2024; 2024:4435791.

PMID: 38715871 PMC: 11074825. DOI: 10.1155/2024/4435791.

Peri-implantitis increases the risk of medication-related osteonecrosis of the jaws associated with osseointegrated implants in rats treated with zoledronate.

Quintao Manhanini Souza E, Toro L, Ganzaroli V, de Oliveira Alvarenga Freire J, Matsumoto M, Casatti C Sci Rep. 2024; 14(1):627.

PMID: 38182598 PMC: 10770413. DOI: 10.1038/s41598-023-49647-4.

Calabria E, Antonelli A, Barone S, Adamo D, Salviati M, Cerra M Dent J (Basel). 2023; 11(6).

PMID: 37366670 PMC: 10297522. DOI: 10.3390/dj11060147.

References

Murphy J, Mannion C . Medication-related osteonecrosis of the jaws and quality of life: review and structured analysis. Br J Oral Maxillofac Surg. 2020; 58(6):619-624. DOI: 10.1016/j.bjoms.2020.03.010. View

Nicolatou-Galitis O, Schiodt M, Amaral Mendes R, Ripamonti C, Hope S, Drudge-Coates L . Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018; 127(2):117-135. DOI: 10.1016/j.oooo.2018.09.008. View

Raj D, Abuzar M, Borromeo G . Bisphosphonates, healthcare professionals and oral health. Gerodontology. 2014; 33(1):135-43. DOI: 10.1111/ger.12141. View

Capocci M, Romeo U, Guerra F, Mannocci A, Tenore G, Annibali S . Medication-related osteonecrosis of the jaws (MRONJ) and quality of life evaluation: a pilot study. Clin Ter. 2017; 168(4):e253-e257. DOI: 10.7417/T.2017.2015. View

Di Fede O, Panzarella V, Mauceri R, Fusco V, Bedogni A, Lo Muzio L . The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention. Biomed Res Int. 2018; 2018:2684924. PMC: 6164200. DOI: 10.1155/2018/2684924. View

Beth-Tasdogan N, Mayer B, Hussein H, Zolk O . Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2017; 10:CD012432. PMC: 6485859. DOI: 10.1002/14651858.CD012432.pub2. View

Sturrock A, Preshaw P, Hayes C, Wilkes S . General dental practitioners' perceptions of, and attitudes towards, improving patient safety through a multidisciplinary approach to the prevention of medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in the North East of.... BMJ Open. 2019; 9(6):e029951. PMC: 6597093. DOI: 10.1136/bmjopen-2019-029951. View

Miksad R, Lai K, Dodson T, Woo S, Treister N, Akinyemi O . Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist. 2011; 16(1):121-32. PMC: 3228058. DOI: 10.1634/theoncologist.2010-0183. View

Valdez J, Brennan M . Impact of Oral Cancer on Quality of Life. Dent Clin North Am. 2017; 62(1):143-154. DOI: 10.1016/j.cden.2017.09.001. View

10.

Moore K, Ford P, Farah C . Support needs and quality of life in oral cancer: a systematic review. Int J Dent Hyg. 2013; 12(1):36-47. DOI: 10.1111/idh.12051. View

11.

Nayfield S, Ganz P, Moinpour C, Cella D, Hailey B . Report from a National Cancer Institute (USA) workshop on quality of life assessment in cancer clinical trials. Qual Life Res. 1992; 1(3):203-10. DOI: 10.1007/BF00635619. View

12.

Hjermstad M, Bergenmar M, Bjordal K, Fisher S, Hofmeister D, Montel S . International field testing of the psychometric properties of an EORTC quality of life module for oral health: the EORTC QLQ-OH15. Support Care Cancer. 2016; 24(9):3915-24. DOI: 10.1007/s00520-016-3216-0. View

13.

Ruggiero S, Dodson T, Fantasia J, Goodday R, Aghaloo T, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72(10):1938-56. DOI: 10.1016/j.joms.2014.04.031. View

14.

McGowan K, McGowan T, Ivanovski S . Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Dis. 2017; 24(4):527-536. DOI: 10.1111/odi.12708. View

15.

Wrazen W, Golec E, Tomaszewska I, Walocha E, Dudkiewicz Z, Tomaszewski K . Preliminary psychometric validation of the Polish version of the EORTC elderly module (QLQ-ELD14). Folia Med Cracov. 2015; 54(2):35-45. View

16.

Gorges J, Wehler B, Kruger M, Singer S . [Oral health-related quality of life in cancer patients]. Laryngorhinootologie. 2018; 97(5):327-333. DOI: 10.1055/a-0573-9741. View

17.

van der Poel M, Oerlemans S, Schouten H, van de Poll-Franse L . Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry. Ann Hematol. 2014; 94(4):651-61. DOI: 10.1007/s00277-014-2264-0. View

18.

Vanleerberghe P, De Witte N, Claes C, Schalock R, Verte D . The quality of life of older people aging in place: a literature review. Qual Life Res. 2017; 26(11):2899-2907. DOI: 10.1007/s11136-017-1651-0. View

19.

Goo A, Shin D, Yang H, Park J, Kim S, Shin J . Cross-cultural application of the Korean version of the EORTC QLQ-ELD14 questionnaire for elderly patients with cancer. J Geriatr Oncol. 2017; 8(4):271-276. DOI: 10.1016/j.jgo.2017.03.001. View

20.

Petrovic I, Rosen E, Matros E, Huryn J, Shah J . Oral rehabilitation of the cancer patient: A formidable challenge. J Surg Oncol. 2018; 117(8):1729-1735. PMC: 6135661. DOI: 10.1002/jso.25075. View